Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A.

PLoS One. 2018 Oct 26;13(10):e0206729. doi: 10.1371/journal.pone.0206729. eCollection 2018.

2.

Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.

Narvaez AJ, Ber S, Crooks A, Emery A, Hardwick B, Guarino Almeida E, Huggins DJ, Perera D, Roberts-Thomson M, Azzarelli R, Hood FE, Prior IA, Walker DW, Boyce R, Boyle RG, Barker SP, Torrance CJ, McKenzie GJ, Venkitaraman AR.

Cell Chem Biol. 2017 Aug 17;24(8):1017-1028.e7. doi: 10.1016/j.chembiol.2017.07.009. Epub 2017 Aug 10.

3.

A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds.

Cairney CJ, Godwin LS, Bilsland AE, Burns S, Stevenson KH, McGarry L, Revie J, Moore JD, Wiggins CM, Collinson RS, Mudd C, Tsonou E, Sadaie M, Bennett DC, Narita M, Torrance CJ, Keith WN.

PLoS Genet. 2017 Aug 14;13(8):e1006942. doi: 10.1371/journal.pgen.1006942. eCollection 2017 Aug.

4.

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A.

PLoS One. 2017 Apr 20;12(4):e0176578. doi: 10.1371/journal.pone.0176578. eCollection 2017. Erratum in: PLoS One. 2018 Oct 26;13(10):e0206729.

5.

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.

Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, Shokat KM, Bandyopadhyay S, Lord CJ, Ashworth A.

Mol Cancer Ther. 2016 Jul;15(7):1472-84. doi: 10.1158/1535-7163.MCT-15-0554. Epub 2016 Jun 30.

6.

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A.

PLoS One. 2016 Apr 18;11(4):e0154007. doi: 10.1371/journal.pone.0154007. eCollection 2016. No abstract available.

7.

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A.

PLoS One. 2016 Feb 16;11(2):e0149099. doi: 10.1371/journal.pone.0149099. eCollection 2016. Erratum in: PLoS One. 2016;11(4):e0154007. PLoS One. 2017 Apr 20;12 (4):e0176578.

8.

Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition.

Sadaie M, Dillon C, Narita M, Young AR, Cairney CJ, Godwin LS, Torrance CJ, Bennett DC, Keith WN, Narita M.

Mol Biol Cell. 2015 Sep 1;26(17):2971-85. doi: 10.1091/mbc.E15-01-0003. Epub 2015 Jul 1. Erratum in: Mol Biol Cell. 2015 Oct 1;26(19):3556. Narita, Masashi [Corrected to Narita, Masako].

9.

Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer.

Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A, Torrance C, Elez E, Tabernero J, Villanueva J.

Clin Cancer Res. 2014 Dec 15;20(24):6346-56. doi: 10.1158/1078-0432.CCR-14-0361. Epub 2014 Oct 16.

10.

Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.

Glaysher S, Bolton LM, Johnson P, Torrance C, Cree IA.

BMC Res Notes. 2014 Jun 25;7:397. doi: 10.1186/1756-0500-7-397.

11.

Targeting EGFR and PI3K pathways in ovarian cancer.

Glaysher S, Bolton LM, Johnson P, Atkey N, Dyson M, Torrance C, Cree IA.

Br J Cancer. 2013 Oct 1;109(7):1786-94. doi: 10.1038/bjc.2013.529. Epub 2013 Sep 10.

12.

TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.).

Zhao J, Lammers P, Torrance CJ, Bader AG.

Mol Ther. 2013 Sep;21(9):1678-86. doi: 10.1038/mt.2013.148. Epub 2013 Jun 18.

13.

Learning objects? Nurse educators' views on using patients for student learning : ethics and consent.

Torrance C, Mansell I, Wilson C.

Educ Health (Abingdon). 2012 Nov;25(2):92-7. doi: 10.4103/1357-6283.103455.

14.

Multiple metabolic alterations exist in mutant PI3K cancers, but only glucose is essential as a nutrient source.

Foster R, Griffin S, Grooby S, Feltell R, Christopherson C, Chang M, Sninsky J, Kwok S, Torrance C.

PLoS One. 2012;7(9):e45061. doi: 10.1371/journal.pone.0045061. Epub 2012 Sep 13.

15.

Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes.

Wallin JJ, Guan J, Edgar KA, Zhou W, Francis R, Torres AC, Haverty PM, Eastham-Anderson J, Arena S, Bardelli A, Griffin S, Goodall JE, Grimshaw KM, Hoeflich KP, Torrance C, Belvin M, Friedman LS.

PLoS One. 2012;7(5):e36402. doi: 10.1371/journal.pone.0036402. Epub 2012 May 3.

16.

Cancer cell senescence: a new frontier in drug development.

Cairney CJ, Bilsland AE, Evans TR, Roffey J, Bennett DC, Narita M, Torrance CJ, Keith WN.

Drug Discov Today. 2012 Mar;17(5-6):269-76. doi: 10.1016/j.drudis.2012.01.019. Epub 2012 Jan 31. Review.

PMID:
22314100
17.

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets.

Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, Downward J, Gore M, Futreal PA, Escudier B, Andre F, Albiges L, Beuselinck B, Oudard S, Hoffmann J, Gyorffy B, Torrance CJ, Boehme KA, Volkmer H, Toschi L, Nicke B, Beck M, Szallasi Z.

Genome Med. 2010 Aug 11;2(8):53. doi: 10.1186/gm174.

18.

Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping.

Richardson CM, Nunns CL, Williamson DS, Parratt MJ, Dokurno P, Howes R, Borgognoni J, Drysdale MJ, Finch H, Hubbard RE, Jackson PS, Kierstan P, Lentzen G, Moore JD, Murray JB, Simmonite H, Surgenor AE, Torrance CJ.

Bioorg Med Chem Lett. 2007 Jul 15;17(14):3880-5. Epub 2007 May 6.

PMID:
17570665
19.
20.

Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.

Richardson CM, Williamson DS, Parratt MJ, Borgognoni J, Cansfield AD, Dokurno P, Francis GL, Howes R, Moore JD, Murray JB, Robertson A, Surgenor AE, Torrance CJ.

Bioorg Med Chem Lett. 2006 Mar 1;16(5):1353-7. Epub 2005 Dec 1.

PMID:
16325401
21.

Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2.

Williamson DS, Parratt MJ, Bower JF, Moore JD, Richardson CM, Dokurno P, Cansfield AD, Francis GL, Hebdon RJ, Howes R, Jackson PS, Lockie AM, Murray JB, Nunns CL, Powles J, Robertson A, Surgenor AE, Torrance CJ.

Bioorg Med Chem Lett. 2005 Feb 15;15(4):863-7.

PMID:
15686876
22.
23.

Reflections on wound care in Australia.

Torrance C.

Br J Nurs. 2001 Mar;10(6 Suppl):S66,S68. No abstract available.

PMID:
12070402
24.

The perennial pressure sore revisited.

Torrance C.

Aust Nurs J. 2000 May;7(10):31. No abstract available.

PMID:
11894345
25.

DEC1 is a downstream target of TGF-beta with sequence-specific transcriptional repressor activities.

Zawel L, Yu J, Torrance CJ, Markowitz S, Kinzler KW, Vogelstein B, Zhou S.

Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2848-53.

26.

Use of isogenic human cancer cells for high-throughput screening and drug discovery.

Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW.

Nat Biotechnol. 2001 Oct;19(10):940-5.

PMID:
11581659
27.

Combinatorial chemoprevention of intestinal neoplasia.

Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM.

Nat Med. 2000 Sep;6(9):1024-8.

PMID:
10973323
28.

Fine tuning the day surgery process.

Coll AM, Moseley L, Torrance C.

Nurs Stand. 1999 Oct 13-19;14(4):39-41. Review.

PMID:
10855175
29.

Assessing tumors in living animals through measurement of urinary beta-human chorionic gonadotropin.

Shih IM, Torrance C, Sokoll LJ, Chan DW, Kinzler KW, Vogelstein B.

Nat Med. 2000 Jun;6(6):711-4. No abstract available.

PMID:
10835692
30.

Disruption of p53 in human cancer cells alters the responses to therapeutic agents.

Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B.

J Clin Invest. 1999 Aug;104(3):263-9.

31.

Use of chaperones in clinics for genitourinary medicine: survey of consultants.

Torrance CJ, Das R, Allison MC.

BMJ. 1999 Jul 17;319(7203):159-60. No abstract available.

32.

Pressure sore survey. Part 3: Locus of control.

Maylor M, Torrance C.

J Wound Care. 1999 Mar;8(3):101-5.

PMID:
10362985
33.

Pressure sore survey. Part 2: Nurses' knowledge.

Maylor M, Torrance C.

J Wound Care. 1999 Feb;8(2):49-52.

PMID:
10232198
34.

Pressure sore survey: Part One.

Torrance C, Maylor M.

J Wound Care. 1999 Jan;8(1):27-30.

PMID:
10214196
35.

Anaemia.

Torrance C.

Nurs Times. 1998 Aug 19-25;94(33):54-7. No abstract available.

PMID:
9791492
36.

The immune system: zoonotic diseases.

Elliot R, Torrance C.

Nurs Times. 1998 May 27-Jun 2;94(21):52-5. Review. No abstract available.

PMID:
9668861
37.

Urine testing--2. urinalysis.

Torrance C, Elley K.

Nurs Times. 1998 Feb 4-10;94(5):suppl 1-2. No abstract available.

PMID:
9547174
38.

Recording temperature-1.

Torrance C, Semple M.

Nurs Times. 1998 Jan 14-20;94(2):suppl 1-2. No abstract available.

PMID:
9510786
39.

Systems and diseases. Hypertension.

Jordan S, Torrance C.

Nurs Times. 1998 Jan 21-27;94(3):50-3. No abstract available.

PMID:
9510768
40.

Practical procedures for nurses. 4.2. Respiration technique and observation--2.

Torrance C, Elley K.

Nurs Times. 1997 Oct 29-Nov 4;93(44):suppl 1-2. No abstract available.

PMID:
9393024
41.

Practical procedures for nurses. 4.1 Respiration technique and observation--1.

Torrance C, Elley K.

Nurs Times. 1997 Oct 22-28;93(43):Suppl 1-2. No abstract available.

PMID:
9386511
42.

Practical procedures for nurses. 2.3. Blood pressure measurement procedure.

Torrance C, Semple M.

Nurs Times. 1997 Oct 1-7;93(40):suppl 1-2. No abstract available.

PMID:
9386481
43.

Practical procedures for nurses. 3.2.

Torrance C, Elley K.

Nurs Times. 1997 Oct 15-21;93(42):suppl 1-2. No abstract available.

PMID:
9370709
44.

Practical procedures for nurses. 3.1. Assessing pulse--1.

Torrance C, Elley K.

Nurs Times. 1997 Oct 8-14;93(41):suppl 1-2. No abstract available.

PMID:
9370688
45.

Blood pressure measurement equipment.

Torrance C, Semple M.

Nurs Times. 1997 Sep 17-23;93(38):suppl 1-2. No abstract available.

PMID:
9362904
46.

Characterization of a low affinity thyroid hormone receptor binding site within the rat GLUT4 gene promoter.

Torrance CJ, Usala SJ, Pessin JE, Dohm GL.

Endocrinology. 1997 Mar;138(3):1215-23.

PMID:
9048629
47.

Effects of thyroid hormone on GLUT4 glucose transporter gene expression and NIDDM in rats.

Torrance CJ, Devente JE, Jones JP, Dohm GL.

Endocrinology. 1997 Mar;138(3):1204-14.

PMID:
9048628
48.
49.
50.

Nurses' and occupational therapists' perceptions of their roles.

Torrance C, Morrison P, Jones CG.

J Psychiatr Ment Health Nurs. 1996 Apr;3(2):134-5. No abstract available.

PMID:
8716806

Supplemental Content

Loading ...
Support Center